Clinical Trials Directory

Trials / Unknown

UnknownNCT04244383

Expression of Inflammasomes in HCV Patients

Expression of Inflammasomes in HCV Patients Before and After Treatment

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Hepatitis C virus has been identified a quarter of a decade ago as a leading cause of chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Only a minority of patients can clear the virus spontaneously during acute infection. Elimination of HCV during acute infection correlates with a rapid induction of innate and a delayed induction of adaptive immune responses. The majority of patients is unable to clear the virus and develops viral persistence despite the ongoing innate and adaptive immune response. The virus usually develops several strategies to escape these immune responses.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTinterleukin IL-1beta and interleukin IL-18pro-inflammatory cytokines measured in the serum

Timeline

Start date
2020-01-01
Primary completion
2020-06-01
Completion
2020-07-01
First posted
2020-01-28
Last updated
2020-01-28

Source: ClinicalTrials.gov record NCT04244383. Inclusion in this directory is not an endorsement.

Expression of Inflammasomes in HCV Patients (NCT04244383) · Clinical Trials Directory